As part of the collaboration, the companies will apply the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX breast cancer test.
Chu Chang, vice president of business development at Genomic Health, said: “This collaboration further expands our efforts to develop genomic tests for a variety of cancers that allow physicians and patients to individualize treatment decisions.”